mTOR inhibitors in kidney transplantation

Abstract

A changing paradigm of treatment of kidney transplant recipients is a new, wider approach to immunosuppression, which should take into account both antiviral and anticancer effects, in addition to cardiovascular protection. Recent observations suggest that the early introduction of mammalian target of rapamycin inhibitors (mTORi) in association with low dose CNI may offer many of these effects. The present manuscript summarizes benefits and contraindications of combinations with mTORi in kidney transplant immunosuppressive strategies.

Key words: kidney transplantation, mTOR inhibitors, immunosuppressive therapy

Sorry, this entry is only available in Italian. For the sake of viewer convenience, the content is shown below in the alternative language. You may click the link to switch the active language.

Introduzione

I protocolli immunodepressivi più comunemente usati nella terapia di mantenimento del trapianto renale includono un inibitore della calcineurina (CNI) (più spesso tacrolimus -Tac che ciclosporina -CsA), un derivato dell’acido micofenolico (micofenolato sodico o micofenolato mofetile– MMF o MPA) e gli steroidi (CS).

 

La visualizzazione dell’intero documento è riservata a Soci attivi, devi essere registrato e aver eseguito la Login con utente e password.